CODXNCMHealthcare·Medical Devices#126 in industry

Co-Diagnostics, Inc.

Reports in 10d· 2026-05-07

-41.5% · 90d

$1.65

-0.02 (-1.20%)

After-Hours $1.65(+0.00)

News

(1)

March 2026

Mar 31, 20263 weeks ago8-KHealthcare

Co-Diagnostics, Inc. — 8-K Filing

CODXCo-Diagnostics, Inc.

# 🧾 What This Document Is This is an 8-K filing, which is a report for major events that shareholders should know about. Attached as Exhibit 99.1 is the company's official press release announcing its financial results for the full year of 2025 and providing a business update. It's a comprehensive

Read summaryView on SEC EDGAR

Key Data

Market Cap$5.9M

Open$1.71

Prev Close$1.67

Day Range$1.64 – $1.72

52W Range$1.35 – $46.50

Volume55,880

P/E (TTM)—

EPS$-35.25

Dividend Yield—

Beta1.43

Revenue Growth76.70%

Next Earnings2026-05-07(10d)

Analyst Ratings

Hold2 analysts

Buy 0Hold 2Sell 0

About

Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is based in Salt Lake City, Utah.

Healthcare · Medical Devices

115 employees

co-dx.com